 |
 Video: What is a Stock Split?
|
|
|
| Regeneron Pharmaceuticals is a biotechnology company. Co.'s products include: EYLEA, which is designed for the treatment of neovascular age-related macular degeneration, diabetic macular edema, macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma and retinopathy of prematurity; Dupixent, which is designed for the treatment of atopic dermatitis, asthma, rhinosinusitis with nasal polyposis, eosinophilic esophagitis (in adults and adolescents) and prurigo nodularis; and Libtayo, which is designed for the treatment of metastatic or locally advanced first-line non-small cell lung cancer and metastatic or recurrent second-line cervical cancer. According to our REGN split history records, Regeneron Pharmaceuticals has had 0 splits. | |
|
Regeneron Pharmaceuticals (REGN) has 0 splits in our REGN split history database.
Looking at the REGN split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Regeneron Pharmaceuticals shares, starting with a $10,000 purchase of REGN, presented on a split-history-adjusted basis factoring in the complete REGN split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/25/2014 |
|
| End date: |
04/23/2024 |
|
| Start price/share: |
$284.42 |
|
| End price/share: |
$907.32 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
219.01% |
|
| Average Annual Total Return: |
12.30% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$31,910.65 |
|
| Years: |
10.00 |
|
|
|
|
|
